Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-MAPB
- Development stage
- Preclinical
- Lead developer
- Clearmind Medicine
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
5-MAPB (5-(2-methylaminopropyl)benzofuran) is a synthetic entactogen of the substituted benzofuran class, structurally related to MDMA. It acts as a triple monoamine reuptake inhibitor and releasing agent (SNDRA), promoting the release and inhibiting the reuptake of serotonin, norepinephrine, and dopamine. Additionally, it acts as an agonist at several serotonin receptors, including 5-HT1B, 5-HT2A, 5-HT2B, and 5-HT2C. Developed preclinically by companies such as Clearmind Medicine, Tactogen, and Klimai Medicine, 5-MAPB is being investigated as a potential alternative to MDMA for psychotherapy-assisted treatment of psychiatric disorders, such as post-traumatic stress disorder (PTSD) and alcohol use disorder, due to its reportedly longer duration of action, lower stimulation, and potentially reduced neurotoxicity compared to MDMA.
- Other names
- 1-(benzofuran-5-yl)-N-methylpropan-2-amine5-(2-methylaminopropyl)benzofuran5-(N-methyl-2-aminopropyl)benzofuran5-MAPBGas Station MollyMDMA 2.0MDMA2.0MDMA-2.0
02
Targets
HTR1B (5-Hydroxytryptamine Receptor 1B)HTR2A (Serotonin receptor 5-HT2A)HTR2B (5-Hydroxytryptamine Receptor 2B)HTR2C (5-hydroxytryptamine 2C receptor)DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on 5-MAPB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 5-MAPB.